Innoviva Stock Price and Value Analysis

Innoviva (NasdaqGS:INVA) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Innoviva to reach your target.

Target type

INVA Free Cash Flow Trend

Free Cash Flow trendline for INVA
Free Cash Flow trendline for Innoviva
CSV

Based on historical returns, we believe that Innoviva can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

Inside the INVA Numbers

INVA Price
(Innoviva stock price per share)
$18.40
[?] INVA Fair Price
(based on intrinsic value)
$16.50
[?] INVA Safety Price (based on a variable margin of safety) $9.90
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 61% lower than other Healthcare stocks
[?] PE Ratio versus Industry 90% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 110%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,495,210 shares shorted. With 66,873,454 shares available for purchase and an average trading volume over the past 10 trading days of 1,125,190, it would take at least 6.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1080014 -58.8
2010 1080014 -75.9
2011 1080014 -90.1
2012 1080014 -129
2013 1080014 -132
2014 1080014 -133
2015 1080014 8.2
2016 1080014 59.7
2017 1080014 141
2018 1080014 223
2019 1080014 257
2020 1080014 313
2021 1080014 364
2022 1080014 202
2023 1080014 141
2024 1080014 189
2025 1080014 197

Download the yearly data as CSV.

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2015 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $1,781 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 5 of those years with dividend payment facts, dividends paid totaled $88.7 million, 12.9% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 4 of those 5 years.

In 6 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $686 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2015 8.2 87.3 25.6 113 1377.4%
2016 59.7 1 78.1 79.1 132.4%
2017 141 0.3 97.5 97.8 69.3%
2018 223 0.1 n/a 0.1 0.0%
2019 257 0 n/a 0 0.0%
2021 364 n/a 394 394 108.3%
2022 202 n/a 8.5 8.5 4.2%
2023 141 n/a 75.7 75.7 53.7%
2024 189 n/a 14.8 14.8 7.8%
2025 197 n/a 4.5 4.5 2.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $24.4 million in 2009 and $411 million in 2025, a compound annual growth rate of 19.3% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 14.7% from 2024 to 2025.

Our estimated free cash flow was $197 million in 2025, 47.8% of revenue. In 2009 the estimated margin was negative 241.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 24.4 -58.8 -241.3%
2010 24.2 -75.9 -313.5%
2011 24.5 -90.1 -367.5%
2012 5.6 -129 -2306.6%
2013 4.5 -132 -2906.3%
2014 8.4 -133 -1575.0%
2015 53.9 8.2 15.2%
2016 134 59.7 44.7%
2017 217 141 64.9%
2018 261 223 85.6%
2019 261 257 98.6%
2020 337 313 93.0%
2021 392 364 92.8%
2022 331 202 60.9%
2023 310 141 45.4%
2024 359 189 52.6%
2025 411 197 47.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $551 million against total liabilities of $462 million, or 119.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 28.3% of total assets in 2025, compared with 106.8% in 2010, a decrease of 78.5 percentage points.

Stockholders equity was $1,173 million in 2025, up from negative equity of -$22.4 million in 2010.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 19.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 331 163 354 -22.4
2011 259 44.8 346 -87.1
2012 369 94.8 214 155
2013 681 144 382 299
2014 522 96.8 745 -223
2015 409 159 752 -343
2016 379 118 732 -353
2017 367 73.3 610 -243
2018 548 62.4 389 159
2019 725 278 383 342
2020 1,000 246 392 608
2021 926 202 400 526
2022 1,231 291 666 566
2023 1,244 194 569 675
2024 1,301 305 610 691
2025 1,635 551 462 1,173

Price Versus Our Estimated Value

Of the 17 fiscal years we can see for Innoviva under its current filer, 11 show positive free cash flow.

Year-to-year variability in free cash flow is volatile, measured at 110%.

Innoviva is priced at $18.40, above our fair value estimate of $16.50 and its safe value of $9.90.

No dividend yield is recorded for Innoviva in our data.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 61% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 90% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Innoviva, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Innoviva (INVA) 1,308 7.8 - - 12% above
Amphastar Pharmaceuticals (AMPH) 1,267 13.6 - 0.8% 108% above
Phibro Animal Health Corporation (PAHC) 1,444 14.2 1.4% - 95% above
ANI Pharmaceuticals (ANIP) 1,624 14.2 - - 200% above
Collegium Pharmaceutical (COLL) 806 23.8 - - 167% above
Perrigo Company plc (PRGO) 2,351 - 7.4% 68.6% 91% below
Prestige Consumer Healthcare (PBH) 2,399 15.6 - 7.6% 49% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1080014.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 6 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-18
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: INVA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in INVA

Does Innoviva have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: INVA

This example shows how we apply the Trendshare checklist to INVA: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 18.40
    • Market cap: $1.3B
    • EPS: 2.35
  2. Step 2 — Valuation checks

    • P/E: 7.83
    • FCF yield: —
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.